Annual Total Liabilities
$180.79 M
+$67.81 M+60.01%
December 31, 2023
Summary
- As of February 7, 2025, KYMR annual total liabilities is $180.79 million, with the most recent change of +$67.81 million (+60.01%) on December 31, 2023.
- During the last 3 years, KYMR annual total liabilities has fallen by -$22.50 million (-11.07%).
- KYMR annual total liabilities is now -11.07% below its all-time high of $203.29 million, reached on December 31, 2020.
Performance
KYMR Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Total Liabilities
$141.91 M
+$815.00 K+0.58%
September 30, 2024
Summary
- As of February 7, 2025, KYMR quarterly total liabilities is $141.91 million, with the most recent change of +$815.00 thousand (+0.58%) on September 30, 2024.
- Over the past year, KYMR quarterly total liabilities has dropped by -$38.88 million (-21.50%).
- KYMR quarterly total liabilities is now -33.27% below its all-time high of $212.68 million, reached on September 30, 2020.
Performance
KYMR Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Total Liabilities Formula
Total Liabilities = Current Liabilities + Long-Term Liabilities
KYMR Total Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +60.0% | -21.5% |
| 3 y3 years | -11.1% | -21.5% |
| 5 y5 years | +129.8% | -21.5% |
KYMR Total Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +60.0% | -21.5% | +25.6% |
| 5 y | 5-year | -11.1% | +60.0% | -33.3% | +84.1% |
| alltime | all time | -11.1% | +129.8% | -33.3% | +84.1% |
Kymera Therapeutics Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $141.91 M(+0.6%) |
| Jun 2024 | - | $141.10 M(-10.2%) |
| Mar 2024 | - | $157.05 M(-13.1%) |
| Dec 2023 | $180.79 M(+60.0%) | $180.79 M(+15.3%) |
| Sep 2023 | - | $156.84 M(+7.0%) |
| Jun 2023 | - | $146.52 M(-3.5%) |
| Mar 2023 | - | $151.90 M(+34.4%) |
| Dec 2022 | $112.98 M | $112.98 M(-10.0%) |
| Sep 2022 | - | $125.59 M(+0.1%) |
| Jun 2022 | - | $125.47 M(-6.6%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2022 | - | $134.34 M(-8.2%) |
| Dec 2021 | $146.27 M(-28.0%) | $146.27 M(-8.2%) |
| Sep 2021 | - | $159.32 M(-9.6%) |
| Jun 2021 | - | $176.28 M(-6.9%) |
| Mar 2021 | - | $189.31 M(-6.9%) |
| Dec 2020 | $203.29 M(+6.4%) | $203.29 M(-4.4%) |
| Sep 2020 | - | $212.68 M(+176.0%) |
| Jun 2020 | - | $77.07 M(-59.7%) |
| Dec 2019 | $191.11 M(+142.9%) | $191.11 M |
| Dec 2018 | $78.67 M | - |
FAQ
- What is Kymera Therapeutics annual total liabilities?
- What is the all time high annual total liabilities for Kymera Therapeutics?
- What is Kymera Therapeutics annual total liabilities year-on-year change?
- What is Kymera Therapeutics quarterly total liabilities?
- What is the all time high quarterly total liabilities for Kymera Therapeutics?
- What is Kymera Therapeutics quarterly total liabilities year-on-year change?
What is Kymera Therapeutics annual total liabilities?
The current annual total liabilities of KYMR is $180.79 M
What is the all time high annual total liabilities for Kymera Therapeutics?
Kymera Therapeutics all-time high annual total liabilities is $203.29 M
What is Kymera Therapeutics annual total liabilities year-on-year change?
Over the past year, KYMR annual total liabilities has changed by +$67.81 M (+60.01%)
What is Kymera Therapeutics quarterly total liabilities?
The current quarterly total liabilities of KYMR is $141.91 M
What is the all time high quarterly total liabilities for Kymera Therapeutics?
Kymera Therapeutics all-time high quarterly total liabilities is $212.68 M
What is Kymera Therapeutics quarterly total liabilities year-on-year change?
Over the past year, KYMR quarterly total liabilities has changed by -$38.88 M (-21.50%)